Aurobindo Pharma Limited
NSE: AUROPHARMA BSE: AUROPHARMA
NSE
1,210.40
-10.00 (-0.82%)
Prev Close
1220.4
Open Price
1186.2
Volume
888,443
Today Low / High
1186.2 / 1223.9
52 WK Low / High
1010 / 1278.6
Range
1,150 - 1,271
BSE
1,211.35
-10.20 (-0.84%)
Prev Close
1221.55
Open Price
1180.05
Volume
43,111
Today Low / High
1180.05 / 1223.25
52 WK Low / High
994.35 / 1278
Range
1,151 - 1,272
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1210.4 (target range: 1,150 - 1,271), reflecting a change of -10 (-0.8194%). On the BSE, it is listed at 1211.35 (target range: 1,151 - 1,272), showing a change of -10.2 (-0.835%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
02 Mar
1,186.20
2.04%
27 Feb
1,225.30
-0.40%
26 Feb
1,217.10
0.30%
25 Feb
1,166.00
3.90%
24 Feb
1,156.30
0.70%
23 Feb
1,166.10
-1.33%
20 Feb
1,173.80
-1.28%
19 Feb
1,156.40
1.30%
18 Feb
1,188.60
-2.44%
17 Feb
1,184.60
0.18%
16 Feb
1,142.00
3.73%
13 Feb
1,149.10
-0.30%
12 Feb
1,146.60
0.99%
11 Feb
1,136.00
0.93%
10 Feb
1,208.00
-6.95%
09 Feb
1,191.00
1.07%
06 Feb
1,181.00
0.85%
Aurobindo Pharma Limited Graph
Aurobindo Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Aurobindo Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,210.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,211.35 | 1,223.46 | 1,101.12 - 1,345.81 |
| 1,235.58 | 988.46 - 1,482.69 | ||
| 1,247.69 | 873.38 - 1,622.00 | ||
| Bearish Scenario | 1,211.35 | 1,199.24 | 1,079.31 - 1,319.16 |
| 1,187.12 | 949.70 - 1,424.55 | ||
| 1,175.01 | 822.51 - 1,527.51 |
Overview of Aurobindo Pharma Limited
ISIN
INE406A01037
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,375,596
Market Cap
703,002,284,479
Last Dividend
4
Official Website
IPO Date
1996-01-15
DCF Diff
-2,270.60
DCF
3,429
Financial Ratios Every Investor Needs
Stock Dividend of AUROPHARMA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-08 | August 08, 25 | 4 | 4 | 2025-08-08 | 2025-08-21 | |
| 2024-02-20 | February 20, 24 | 1.5 | 1.5 | 2024-02-20 | 2024-03-04 | |
| 2023-11-20 | November 20, 23 | 3 | 3 | 2023-11-20 | 2023-12-04 | |
| 2023-02-17 | February 17, 23 | 3 | 3 | 2023-02-17 | 2023-03-03 | |
| 2022-06-06 | June 06, 22 | 4.5 | 4.5 | 2022-06-07 | 2022-06-15 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 31,723.73 Cr | 13,483.86 Cr | 18,239.87 Cr | 0.5750 | 1,691.99 Cr | 0.00 Cr | 12,000.92 Cr | 3,485.88 Cr | 59.81 | 6,436.35 Cr | 0.1099 |
| 2024-03-31 | 29,001.87 Cr | 12,985.69 Cr | 16,016.18 Cr | 0.5522 | 1,522.43 Cr | 0.00 Cr | 10,450.39 Cr | 3,172.97 Cr | 54.15 | 5,764.12 Cr | 0.1094 |
| 2023-03-31 | 24,855.38 Cr | 11,641.67 Cr | 13,213.71 Cr | 0.5316 | 1,452.84 Cr | 0.00 Cr | 8,104.86 Cr | 1,927.50 Cr | 32.90 | 3,634.41 Cr | 0.0775 |
| 2022-03-31 | 23,455.49 Cr | 10,449.88 Cr | 13,005.61 Cr | 0.5545 | 1,624.62 Cr | 0.00 Cr | 7,805.88 Cr | 2,648.15 Cr | 45.20 | 4,311.42 Cr | 0.1129 |
| 2021-03-31 | 24,774.62 Cr | 10,189.77 Cr | 14,584.85 Cr | 0.5887 | 1,524.05 Cr | 0.00 Cr | 9,403.24 Cr | 5,334.84 Cr | 91.05 | 5,394.71 Cr | 0.2153 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 8,235.49 Cr | 49,784.97 Cr | 17,138.04 Cr | 32,653.3200 Cr | 8,262.87 Cr | 27.38 Cr | 10,543.72 Cr | 15,455.43 Cr | 103.79 Cr | 47.57 Cr | 251.70 Cr | 14,682.3400 Cr |
| 2024-03-31 | 3,393.48 Cr | 45,071.51 Cr | 15,220.71 Cr | 29,842.8000 Cr | 6,647.63 Cr | 3,254.15 Cr | 9,808.23 Cr | 14,411.69 Cr | 270.29 Cr | 36.35 Cr | -2,202.63 Cr | 12,199.1300 Cr |
| 2023-03-31 | 4,396.29 Cr | 39,889.99 Cr | 13,038.14 Cr | 26,839.8500 Cr | 5,286.21 Cr | 889.92 Cr | 8,511.23 Cr | 12,803.60 Cr | 388.87 Cr | 0.00 Cr | -1,285.23 Cr | 11,493.7800 Cr |
| 2022-03-31 | 4,162.51 Cr | 33,921.72 Cr | 9,347.67 Cr | 24,575.9800 Cr | 3,278.96 Cr | -883.55 Cr | 7,553.85 Cr | 10,769.91 Cr | 567.85 Cr | 0.00 Cr | 223.17 Cr | 8,155.9800 Cr |
| 2021-03-31 | 5,373.47 Cr | 33,853.99 Cr | 11,925.00 Cr | 21,929.8700 Cr | 5,339.08 Cr | -34.39 Cr | 9,026.57 Cr | 9,315.51 Cr | 0.00 Cr | 0.01 Cr | 431.21 Cr | 10,665.0500 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3,924.6200 Cr | -1,875.8000 Cr | 119.7800 Cr | 1,956.7600 Cr | 2,178.3600 Cr | 5,563.7900 Cr | -1,967.8600 Cr | 3,485.8800 Cr | 1,603.7100 Cr | -1.0400 Cr | -735.4900 Cr |
| 2024-03-31 | 2,434.5200 Cr | -4,255.9500 Cr | 800.4200 Cr | -1,126.9800 Cr | -1,006.8400 Cr | 3,385.4300 Cr | -2,780.3300 Cr | 3,172.9700 Cr | 1,461.3100 Cr | -263.6400 Cr | -1,303.6800 Cr |
| 2023-03-31 | 2,386.7500 Cr | -3,977.7500 Cr | 1,814.4100 Cr | -333.6500 Cr | 229.7600 Cr | 4,392.2700 Cr | -2,403.8000 Cr | 2,612.5000 Cr | 2,457.6100 Cr | -439.5300 Cr | -926.7000 Cr |
| 2022-03-31 | 5,016.4800 Cr | -3,211.5600 Cr | -2,969.2700 Cr | 2,311.8400 Cr | -1,167.4000 Cr | 4,162.5100 Cr | -2,052.9100 Cr | 3,372.7400 Cr | -2,553.9300 Cr | -263.7000 Cr | 1,497.5200 Cr |
| 2021-03-31 | 3,329.0500 Cr | 598.6900 Cr | -1,364.8100 Cr | 1,455.2400 Cr | 2,583.0900 Cr | 5,329.9100 Cr | -1,873.8100 Cr | 7,343.5900 Cr | -958.9600 Cr | -234.3100 Cr | -1,593.5800 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 8,645.90 Cr | 5,256.00 Cr | 3,389.90 Cr | 0.3921 | 1,308.61 Cr | 910.28 Cr | 15.67 | 1,895.65 Cr | 0.1053 |
| 2025-09-30 | 8,285.70 Cr | 5,045.38 Cr | 3,240.32 Cr | 0.3911 | 1,248.91 Cr | 848.45 Cr | 14.61 | 1,798.69 Cr | 0.1024 |
| 2025-06-30 | 7,868.14 Cr | 3,239.22 Cr | 4,628.92 Cr | 0.5883 | 3,400.12 Cr | 824.75 Cr | 14.20 | 1,610.08 Cr | 0.1048 |
| 2025-03-31 | 8,382.12 Cr | 3,885.50 Cr | 4,496.62 Cr | 0.5365 | 1,570.65 Cr | 903.47 Cr | 15.56 | 1,740.91 Cr | 0.1078 |
| 2024-12-31 | 7,978.52 Cr | 3,315.41 Cr | 4,663.11 Cr | 0.5845 | 3,531.56 Cr | 845.81 Cr | 14.56 | 1,552.43 Cr | 0.1060 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 8,891.39 Cr | 1.02 Cr | 8,892.41 Cr | 5,907.74 Cr | 11,191.88 Cr | 28,648.71 Cr | 16,320.13 Cr | 52,545.60 Cr | 17,511.74 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 8,235.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -32,646.93 Cr |
| 2025-03-31 | 8,235.49 Cr | 2,632.32 Cr | 8,235.50 Cr | 5,761.49 Cr | 10,543.72 Cr | 27,162.46 Cr | 15,455.43 Cr | 49,784.97 Cr | 17,138.04 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 6,868.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -30,884.96 Cr |
| 2024-09-30 | 6,839.71 Cr | 28.52 Cr | 6,868.23 Cr | 5,402.16 Cr | 10,431.86 Cr | 26,225.64 Cr | 14,924.13 Cr | 48,094.45 Cr | 17,209.49 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 824.75 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 903.47 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 845.81 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 817.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 919.22 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-07-20 | July 20, 15 | 2:1 |
| 2011-02-10 | February 10, 11 | 5:1 |
| 2003-10-23 | October 23, 03 | 2:1 |
| 2000-03-20 | March 20, 00 | 2:1 |
| 1998-10-26 | October 26, 98 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,752.50 | ₹4,204,834,534,925.00 | ₹3,919,016.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,403.50 | ₹1,699,928,052,030.00 | ₹300,339.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,369.20 | ₹1,478,735,816,448.00 | ₹231,761.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,294.40 | ₹1,077,692,658,712.00 | ₹1,052,141.00 |
| Lupin Limited | LUPIN | ₹2,311.10 | ₹1,056,272,077,300.00 | ₹580,904.00 |
| Mankind Pharma Limited | MANKIND | ₹2,245.50 | ₹926,953,789,176.00 | ₹545,012.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹906.90 | ₹912,553,605,531.00 | ₹518,610.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,210.40 | ₹703,002,284,479.00 | ₹888,443.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,566.00 | ₹665,498,790,000.00 | ₹54,260.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,123.30 | ₹599,196,977,750.00 | ₹315,603.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,065.00 | ₹574,947,259,830.00 | ₹2,261,423.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,513.00 | ₹383,854,481,834.00 | ₹115,864.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,967.80 | ₹370,783,944,907.00 | ₹82,523.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,077.40 | ₹333,479,924,060.00 | ₹259,727.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,445.30 | ₹273,989,192,062.00 | ₹128,185.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,801.00 | ₹220,025,000,000.00 | ₹7,555.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,310.00 | ₹212,864,741,390.00 | ₹350,318.00 |
| Eris Lifesciences Limited | ERIS | ₹1,360.40 | ₹185,309,458,516.00 | ₹144,678.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹956.25 | ₹171,273,813,188.00 | ₹1,073,075.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,096.00 | ₹168,020,226,344.00 | ₹39,142.00 |
| Granules India Limited | GRANULES | ₹574.40 | ₹139,388,910,470.00 | ₹468,097.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹705.25 | ₹138,626,143,201.00 | ₹58,524.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹850.35 | ₹134,669,715,212.00 | ₹109,605.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,672.90 | ₹127,159,966,238.00 | ₹90,254.00 |
| Cohance Lifesciences Limited | COHANCE | ₹303.20 | ₹115,994,356,848.00 | ₹708,355.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹914.35 | ₹112,223,661,600.00 | ₹57,229.00 |
| Viyash Scientific Limited | VIYASH | ₹199.94 | ₹87,214,939,466.00 | ₹1,642,591.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,987.60 | ₹82,791,077,663.00 | ₹22,174.00 |
| Strides Pharma Science Limited | STAR | ₹842.45 | ₹77,650,902,909.00 | ₹213,842.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹474.45 | ₹72,639,271,418.00 | ₹129,501.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹705.75 | ₹63,974,324,918.00 | ₹179,889.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹323.55 | ₹63,280,496,567.00 | ₹233,105.00 |
| FDC Limited | FDC | ₹372.05 | ₹60,573,491,752.00 | ₹125,826.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹125.92 | ₹40,863,758,361.00 | ₹481,526.00 |
| Innova Captab Limited | INNOVACAP | ₹664.30 | ₹38,014,520,335.00 | ₹27,921.00 |
| Suven Life Sciences Limited | SUVEN | ₹141.99 | ₹32,934,838,780.00 | ₹224,892.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹357.30 | ₹32,610,771,000.00 | ₹127,791.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹296.10 | ₹32,264,614,967.00 | ₹76,769.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹600.10 | ₹30,436,534,911.00 | ₹94,277.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,805.80 | ₹29,866,153,287.00 | ₹7,962.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹278.55 | ₹27,933,692,046.00 | ₹45,963.00 |
Key Executives
Associate President of HR
K. Suresh Kumar
Gender: Not Specified
Year Born:
President of Biologics, Chief Executive Officer of Biologics, Vaccines and Peptid & Director
Makkapati Satakarni
Gender: Not Specified
Year Born: 1981
Chief Scientific Officer
Parveen Kumar Luthra
Gender: Not Specified
Year Born: 1971
President of Technical
S. Vijaya Kumar
Gender: Not Specified
Year Born: 1966
Compliance Officer & Company Secretary
Baddigam Adi Reddy
Gender: male
Year Born:
Senior Vice President of Admin
Ilapakurty S R Chandra Rao
Gender: male
Year Born:
Vice Chairman & MD
Kambam Nityananda Reddy
Gender: male
Year Born: 1958
Whole-Time Director
Mettu Madan Mohan Reddy
Gender: male
Year Born: 1960
Senior Vice President of Accounts
Mula Surya Narayana Murthy
Gender: male
Year Born:
Chief Financial Officer
Santhanam Subramanian
Gender: male
Year Born: 1961
FAQs about Aurobindo Pharma Limited
Who is the CEO of the company?
The CEO is Makkapati Satakarni.
What is the current market price of the stock?
The current price is ₹1,210.40.
What is the 52-week price range?
The range is ₹1010-1278.6.
What is the market capitalization of the company?
The market capitalization is ₹70,300.23 crores.
What is the dividend yield?
The dividend yield is 0.33%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 20.16.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Aurobindo Pharma Limited (ISIN: INE406A01037) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹70,300.23 crores and an average daily volume of 1,375,596 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹4.